In a filing, Humacyte Inc revealed its Director Dougan Brady W unloaded Company’s shares for reported $1.79 million on Aug 19 ’25. In the deal valued at $1.63 per share,1,100,000 shares were sold. As a result of this transaction, Dougan Brady W now holds 591,685 shares worth roughly $0.89 million.
Then, Dougan Brady W sold 549,360 shares, generating $1,005,329 in total proceeds. Upon selling the shares at $1.83, the Director now owns 1,691,685 shares.
Before that, Dougan Brady W sold 591,685 shares. Humacyte Inc shares valued at $934,862 were divested by the Director at a price of $1.58 per share. As a result of the transaction, Dougan Brady W now holds 0 shares, worth roughly $0.0.
A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in mid December has reiterated a ‘”a Buy”‘ rating for it. H.C. Wainwright began covering HUMA with “Buy” recommendation on December 11, 2023. Piper Sandler revised its rating on August 14, 2023. It rated HUMA as “a Neutral” which previously was an “an Underweight”.
Price Performance Review of HUMA
On Monday, Humacyte Inc [NASDAQ:HUMA] saw its stock fall -5.06% to $1.5. Over the last five days, the stock has lost -16.67%. Humacyte Inc shares have fallen nearly -76.82% since the year began. Nevertheless, the stocks have fallen -70.30% over the past one year. While a 52-week high of $7.48 was reached on 01/02/25, a 52-week low of $1.15 was recorded on 04/08/25.
Levels Of Support And Resistance For HUMA Stock
The 24-hour chart illustrates a support level at 1.4733, which if violated will result in even more drops to 1.4467. On the upside, there is a resistance level at 1.5533. A further resistance level may holdings at 1.6067.
How much short interest is there in Humacyte Inc?
A steep rise in short interest was recorded in Humacyte Inc stocks on 2025-07-31, growing by 1.29 million shares to a total of 31.87 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-30 was 30.58 million shares. There was a rise of 4.05%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 22, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $6 price target.
